Jefferies Names Possible Hedge Fund Short Targets
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
Go back to Jefferies Names Possible Hedge Fund Short Targets
February 1, 2021 7:33 AM EST
Biogen Inc. (NASDAQ: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has approved a new intramuscular (IM) injection route of administration for PLEGRIDY® (peginterferon beta-1a) for the treatment of relapsing forms of multiple sclerosis (MS). The new IM administration offers people living with relapsing MS the well-characterized efficacy and safety of PLEGRIDY with the potential for significantly reduced injection site reactions. This... More
February 1, 2021 6:49 AM EST
RBC Capital analyst Randall Stanicky reiterated a Sector Perform rating and $42.00 price target on Pfizer (NYSE: PFE) ahead of the company's 4Q earnings release. PFE is set to report 4Q results this Tuesday. Stanicky thinks the 4Q set up is relatively favorable on the back... More
January 29, 2021 8:48 AM EST
Stifel analyst Paul Matteis upgraded Biogen (NASDAQ: BIIB) from Hold to Buy with a price target of $358.00 (from $258.00).
The analyst comments "Our initial reaction after the Aducanumab AdComm was that the path to FDA approval seems challenging. Since, Biogen management's... More
